Krajina: Kanada
Jazyk: angličtina
Zdroj: Health Canada
PERICIAZINE
SEARCHLIGHT PHARMA INC
N05AC01
PERICIAZINE
10MG
CAPSULE
PERICIAZINE 10MG
ORAL
15G/50G
Prescription
PHENOTHIAZINES
Active ingredient group (AIG) number: 0106194001; AHFS:
APPROVED
2000-10-17
PRODUCT MONOGRAPH PR NEULEPTIL _PERICIAZINE CAPSULES _ _ _ _PERICIAZINE ORAL DROPS _ _ _ _ _ _ _ _ _ PSYCHOTROPIC AGENT Searchlight Pharma Inc. 1600 Notre-Dame West, suite 312 Montreal, Quebec H3J 1M1 Date of Preparation: JAN 26, 2023 Submission Control No.: 271076 1 PR NEULEPTIL® _PERICIAZINE CAPSULES _ _PERICIAZINE ORAL DROPS _ PSYCHOTROPIC AGENT ACTION Periciazine is a phenothiazine of the piperidine group. It has been shown to reduce pathologic arousal and affective tension in some psychotic patients, while the symptoms of abnormal mental integration are relatively unaffected. It is a sedative phenothiazine with weak antipsychotic properties. It also has adrenolytic, anticholinergic metabolic and endocrine effects, and an action on the extrapyramidal system. Like other phenothiazines, it is presumed to act principally in the subcortical areas, by producing what has been described as a central adrenergic blockade. INDICATIONS As adjunctive medication in some psychotic patients, for the control of residual prevailing hostility, impulsiveness and aggressiveness. CONTRAINDICATIONS Circulatory collapse, altered states of consciousness or comatose states, particularly when they are due to intoxication with central depressant drugs such as alcohol, hypnotics, analgesics, narcotics, etc. It should also not be administered in association with spinal or regional anesthesia. Periciazine is contraindicated in patients with a history of blood dyscrasias, liver disease or hypersensitivity related to other phenothiazines. WARNINGS Geriatrics and Debilitated Patients: Particular care should be exercised when periciazine is given to elderly or debilitated patients as some appear to be unduly sensitive to the effects of the drug. Elderly Patients with Dementia: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk o Prečítajte si celý dokument